Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF [electronic resource] by
- Antonello, Zeus A
- Hsu, Nancy
- Bhasin, Manoj
- Roti, Giovanni
- Joshi, Mukta
- Van Hummelen, Paul
- Ye, Emily
- Lo, Agnes S
- Karumanchi, S Ananth
- Bryke, Christine R
- Nucera, Carmelo
Publication details: Oncotarget Oct 2017
In:
Oncotarget vol. 8
Availability: No items available.
|
|
6.
|
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. [electronic resource] by
- Zhang, Sen
- Anjum, Rana
- Squillace, Rachel
- Nadworny, Sara
- Zhou, Tianjun
- Keats, Jeff
- Ning, Yaoyu
- Wardwell, Scott D
- Miller, David
- Song, Youngchul
- Eichinger, Lindsey
- Moran, Lauren
- Huang, Wei-Sheng
- Liu, Shuangying
- Zou, Dong
- Wang, Yihan
- Mohemmad, Qurish
- Jang, Hyun Gyung
- Ye, Emily
- Narasimhan, Narayana
- Wang, Frank
- Miret, Juan
- Zhu, Xiaotian
- Clackson, Tim
- Dalgarno, David
- Shakespeare, William C
- Rivera, Victor M
Producer: 20180117
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 22
Availability: No items available.
|